STAT Plus BristolMyers Squibb turns to an AI startup to accelerate cancer research

STAT Plus: Bristol-Myers Squibb turns to an AI startup to accelerate cancer research

Bristol-Myers Squibb, seeking to re-energize its cancer pipeline, is turning to an artificial intelligence startup, Concerto, to accelerate its clinical trials by using real-world data. $BMY

More From BioPortfolio on "STAT Plus: Bristol-Myers Squibb turns to an AI startup to accelerate cancer research"